{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=5", "query": { "intervention": "bispecific antibody", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 362, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=bispecific+antibody&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T15:37:31.800Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04083534", "title": "First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "REGN5459", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2019-09-26", "completion_date": "2025-05-01", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 7, "location_summary": "Indianapolis, Indiana • Ann Arbor, Michigan • Rochester, Minnesota + 4 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04083534" }, { "nct_id": "NCT03915379", "title": "A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "JNJ-67571244", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2019-03-28", "completion_date": "2022-03-28", "has_results": false, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 9, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Hackensack, New Jersey + 5 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03915379" }, { "nct_id": "NCT05733351", "title": "Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Sensitive Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "PSMA PET Scan", "type": "PROCEDURE" }, { "name": "Vudalimab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 4, "start_date": "2023-08-03", "completion_date": "2025-06-12", "has_results": false, "last_update_posted_date": "2025-09-15", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05733351" }, { "nct_id": "NCT03147612", "title": "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia With BCR-ABL1", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Vincristine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2018-02-08", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03147612" }, { "nct_id": "NCT03983395", "title": "Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "ISB 1302 250 ng/kg", "type": "BIOLOGICAL" }, { "name": "ISB 1302 325 ng/kg", "type": "BIOLOGICAL" }, { "name": "ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22", "type": "BIOLOGICAL" }, { "name": "ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22", "type": "BIOLOGICAL" }, { "name": "ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22", "type": "BIOLOGICAL" }, { "name": "ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22", "type": "BIOLOGICAL" }, { "name": "ISB 1302 escalating doses,1200 ng/kg D15,22", "type": "BIOLOGICAL" }, { "name": "ISB 1302 at the MTD and/or RP2D dose", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Ichnos Sciences SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2020-04-08", "completion_date": "2020-07-24", "has_results": false, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 5, "location_summary": "Gilbert, Arizona • Los Angeles, California • Louisville, Kentucky + 2 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03983395" }, { "nct_id": "NCT05090566", "title": "MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elranatamab + Nirogacestat", "type": "DRUG" }, { "name": "Elranatamab + lenalidomide + dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2021-10-27", "completion_date": "2026-03-11", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 22, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Beverly Hills, California + 8 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05090566" }, { "nct_id": "NCT02811679", "title": "A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Blinatumomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-08", "completion_date": "2023-12", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02811679" }, { "nct_id": "NCT04864522", "title": "Phase I/II Study of SLAMF7 FPBMC/CS-1 FPBMC in Relapsed/Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "SLAMF7 FPBMC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-08", "completion_date": "2023-11", "has_results": false, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04864522" }, { "nct_id": "NCT02766699", "title": "A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Astrocytoma, Grade IV" ], "interventions": [ { "name": "EGFR(V)-EDV-Dox", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Engeneic Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2016-10-25", "completion_date": "2022-03-30", "has_results": false, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02766699" }, { "nct_id": "NCT06712316", "title": "Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1580, "start_date": "2025-01-07", "completion_date": "2031-12", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-17T15:37:31.800Z", "location_count": 53, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Concord, California + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Vail", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712316" } ] }